{
    "nctId": "NCT02883790",
    "briefTitle": "Effects of Somnage\u00ae in the Management on Sleep and Mood in Cancer Patients",
    "officialTitle": "Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled, Study to Evaluate the Effects of Melatonin (Somnage\u00ae- Food Supplement) in the Management on Sleep Quality and Mood Alteration in Cancer Patients",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Lung Cancer, Colon Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 3,
    "primaryOutcomeMeasure": "Quality of sleep assessed using the PSQI scale",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Male and Females aged between 18 and 75 years (included)\n2. Pittsburgh Sleep Quality Index (PSQI) score \u2265 5\n3. Diagnosed for breast, lung or colon-rectal cancer\n4. Metastatic first chemotherapy line\n5. Planned duration of chemotherapy treatment at least 63 days\n6. Negative to pregnancy test\n7. Patients able to swallow\n\nExclusion Criteria:\n\n1. Known hypersensitivity reaction to Melatonin, Zinc or Magnesium or any components of the product\n2. Known current drug or alcohol abuse.\n3. Use of other investigational drug(s) within 30 days before study entry or during the study\n4. Clinically significant findings on physical examination or presence of known clinically significant disease that would interfere with study evaluation\n5. Patients treated with benzodiazepines, hypnotic, anticonvulsant, antipsychotic or antidepressant drugs in the two months before screening visit\n6. Patients receiving or planned to receive warfarin\n7. Chronic treatment with steroids with daily dose over 10 mg prednisone or equivalent product\n8. Brain metastases",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}